AEVA vs NVDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AEVA's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score (with a Debt/Equity ratio of 7.75) raises significant bankruptcy risk. Despite strong revenue growth of 108.5% YoY, the company operates at a massive loss, with negative margins across all key metrics and a negative ROE of -258.39%. Insider selling totaling $22.37M over six months, including large sales by top executives, reinforces bearish sentiment. Although analysts rate it 'strong_buy' with a target of $24.10, the current price of $15.16 reflects a 5-year decline of 81.2%, suggesting deep skepticism from the market.
NVDA shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Key strengths include strong valuation and growth metrics. Price trades at a 20.7% premium to fair value estimate ($144.55), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
AEVA vs NVDA: Head-to-Head Comparison
This page compares Aeva Technologies, Inc. (AEVA) and NVIDIA Corporation (NVDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.